Patents by Inventor Wenjia Li

Wenjia Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250223331
    Abstract: A GLP-1/GIP dual-targeted polypeptide, containing a first polypeptide having the following amino acid sequence: X1X2X3GT FX4SDY SX5X6X7X8 X9X10X11X12X13 X14FX15X16W LX17X18X19. The GLP-1/GIP dual-targeted polypeptide can effectively reduce the weight and blood sugar level.
    Type: Application
    Filed: September 1, 2022
    Publication date: July 10, 2025
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Peng JIANG, Lin XIAO, Linjun ZHOU, Limei HUANG, Min YANG, Yan JIANG, Ningyuan SUN, Jianming MAO, Yong LI, Lijia LI, Linfeng GUO, Jing LI, Wenjia LI
  • Publication number: 20250179142
    Abstract: A fusion protein of GLP-1 and GDF15 and the use thereof. The fusion protein comprises a first polypeptide fragment, a second polypeptide fragment and a third polypeptide fragment which are sequentially connected from an amino terminal to a carboxyl terminal; and the three polypeptide fragments sequentially comprise a GLP-1 polypeptide, an immunoglobulin Fc region and a GDF15 active domain. The fusion protein provided has a GLP-1 and GDF15 dual-target activity. The fusion protein as a whole has excellent physicochemical properties and stability, and the two target molecules of GLP-1 and GDF15 have a good activity and pharmacokinetic balance, facilitating the exertion of a dual-target effect.
    Type: Application
    Filed: December 30, 2022
    Publication date: June 5, 2025
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Jiangyu YAN, Lin XIAO, Junnan ZENG, Qingwei GONG, Xiaoli CHENG, Xiaoying LIU, Wenjia LI
  • Publication number: 20250099586
    Abstract: Provided is a set of viral vectors, comprising: a first viral vector that carries a first nucleic acid molecule encoding an envelope protein, and a second viral vector that carries a second nucleic acid molecule encoding a fusion protein, the fusion protein comprising: a single-chain antibody capable of binding to CD28 or CD3, and a C-terminal domain, comprising a transmembrane region and an intracellular region, of the envelope protein. The C terminal of the single-chain antibody is connected to the N terminal of the C-terminal domain of the envelope protein, and the envelope protein and the fusion protein are in a non-fusion form. Also provided are a method for obtaining a lentivirus and an obtained lentivirus, a method for introducing a lentivirus into an unactivated T lymphocyte, a method for expressing a target gene, a method for obtaining a CAR-T cell and an obtained CAR-T cell, a pharmaceutical composition, and a use thereof.
    Type: Application
    Filed: January 16, 2023
    Publication date: March 27, 2025
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xiaodan YANG, Shiyou CHEN, Xiuqin ZHU, Linsheng LI, Junji DONG, Guanghui ZHAO, Lijia LI, Xiaofeng CHEN, Wenjia LI
  • Publication number: 20250002574
    Abstract: An antibody or an antigen-binding fragment thereof capable of specifically recognizing IL-11. The antibody includes heavy chain variable region CDRs as shown in SEQ ID NOs: 4-6, light chain variable region CDRs as shown in SEQ ID NOs: 37-39, heavy chain framework regions as shown in SEQ ID NOs: 67-70, and light chain framework regions as shown in SEQ ID NOs: 71-74, respectively. The antibody has low immunogenicity and can specifically target and bind to IL-11, so as to block binding of IL-11 to an IL-11 receptor.
    Type: Application
    Filed: August 11, 2022
    Publication date: January 2, 2025
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Jiatao ZHOU, Cangsha CHEN, Yincai WANG, Miaoxing JIE, Junji DONG, Wenjia LI
  • Publication number: 20240391971
    Abstract: A fusion protein comprises an Fc variant and a GDF15 active domain, wherein the Fc variant has amino acid substitutions at position 356 and/or position 439 of the IgG Fc according to EU numbering and still has the ability to form homodimer. By fusing the Fc variant with the GDF15 active domain, the Fc-GDF15 fusion protein has significantly improved physicochemical properties and recombinant expression levels, has in vitro activity equivalent to or better than natural GDF15 molecules, and has significantly prolonged in vivo circulating half-life, which can support the dosing frequency of once every two weeks or even once a month.
    Type: Application
    Filed: August 23, 2022
    Publication date: November 28, 2024
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Jiangyu YAN, Rongbo CAO, Lin XIAO, Junnan ZENG, Limei HUANG, Xiling WEI, Zhaofeng LI, Qingwei GONG, Xingguo YAN, Jing LI, Danxia HUANG, Xiaofeng CHEN, Wenjia LI
  • Publication number: 20240374692
    Abstract: A novel acylated insulin analog is provided as well as a side chain compound that can be used to prepare the acylated insulin analog, a pharmaceutical composition thereof, a pharmaceutical use, an administration method and a preparation method. The acylated insulin analog can be used for the treatment of diabetes. It has the effect as a weekly preparation or a longer-acting insulin preparation and can be used for the treatment once a week or less frequently, increasing the compliance of diabetic patients.
    Type: Application
    Filed: May 23, 2022
    Publication date: November 14, 2024
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Baoye ZHENG, Dan LEI, Haigang WANG, Shushan LIN, Zhizhu ZHAN, Qian WANG, Qiuyan LIU, Yangling HU, Zilan YANG, Yan JIANG, Wenjia LI
  • Publication number: 20240350588
    Abstract: A GDF15 fusion protein and a method for treating obesity using same. The fusion protein includes an Fc variant and a GDF15 active domain, wherein the Fc variant has an amino acid substitution at position 356 and/or position 439 of the IgG Fc according to EU numbering and still has the ability to form a homodimer. By means of fusing the Fc variant with the GDF15 active domain, the Fc-GDF15 fusion protein has significantly improved physical and chemical properties and recombinant expression level, has an in vitro activity comparable to or better than that of a natural GDF15 molecule, and has a significantly prolonged in vivo cyclic half-life, which may support the dosing frequency once every two weeks or even once a month.
    Type: Application
    Filed: August 23, 2022
    Publication date: October 24, 2024
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Jiangyu YAN, Rongbo CAO, Lin XIAO, Junnan ZENG, Limei HUANG, Xiling WEI, Zhaofeng LI, Qingwei GONG, Xingguo YAN, Jing LI, Danxia HUANG, Xiaofeng CHEN, Wenjia LI
  • Publication number: 20240343770
    Abstract: GDF15 fusion proteins and uses thereof, the fusion protein includes an Fc variant and a GDF15 active domain, wherein the Fc variant has amino acid substitutions at position 356 and/or position 439 of the IgG Fc according to EU numbering and still has the ability to form homodimer. By fusing the Fc variant with the GDF15 active domain, the Fc-GDF15 fusion protein has significantly improved physicochemical properties and recombinant expression levels, has in vitro activity equivalent to or better than natural GDF15 molecules, and has significantly prolonged in vivo circulating half-life, which can support the dosing frequency of once every two weeks or even once a month.
    Type: Application
    Filed: August 23, 2022
    Publication date: October 17, 2024
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Jiangyu YAN, Rongbo CAO, Lin XIAO, Junnan ZENG, Limei HUANG, Xiling WEI, Zhaofeng LI, Qingwie GONG, Xingguo YAN, Jing LI, Danxia HUANG, Xiaofeng CHEN, Wenjia LI
  • Publication number: 20240165202
    Abstract: A method of treating fatty liver-related diseases in a patient includes administering to the patient a therapeutically effective amount of medicament manufactured from a FGF21 polypeptide, FGF21 fusion protein, or dual-fusion protein of FGF21 polypeptide and GLP-1 or a functional variant thereof.
    Type: Application
    Filed: March 18, 2022
    Publication date: May 23, 2024
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Shushan LIN, Yu LI, Xianglei GAO, Can XIE, Jiangyu YAN, Liang LIU, Xiaoping LI, Xiaofeng CHEN, Wenjia LI
  • Publication number: 20240150387
    Abstract: A glucocerebroside compound, a pharmaceutical composition thereof, and the use of the glucocerebroside compound and the pharmaceutical composition thereof in the preparation of drugs for preventing or treating immune-related diseases.
    Type: Application
    Filed: April 2, 2021
    Publication date: May 9, 2024
    Applicant: DONGGUAN HEC CORDYCEPS R&D CO., LTD.
    Inventors: Hao GAO, Zhengming QIAN, Chuanxi WANG, Shutai JIANG, Xinsheng YAO, Wenjia LI, Qi HUANG
  • Publication number: 20240076690
    Abstract: A group of viral vectors including: first viral vector, wherein first viral vector carries first nucleic acid molecule, and the first nucleic acid molecule encodes envelope protein; second viral vector, wherein second viral vector carries second nucleic acid molecule, the second nucleic acid molecule encodes fusion protein, the fusion protein includes single-chain antibody and C-terminal domain of envelope protein, the C-terminal domain of envelope protein includes transmembrane region and intracellular region of envelope protein, the C-terminus of single-chain antibody connects with N-terminus of C-terminal domain of envelope protein, the single-chain antibody targets a specific antigen; first nucleic acid molecule and second nucleic acid molecule are arranged to express envelope protein and fusion protein, and the envelope protein and the fusion protein are in non-fusion form.
    Type: Application
    Filed: September 29, 2021
    Publication date: March 7, 2024
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xiaodan YANG, Shiyou CHEN, Xiuqin ZHU, Junji DONG, Xiaofeng CHEN, Wenjia LI
  • Publication number: 20230357411
    Abstract: A humanized antibody or antigen-binding fragment thereof capable of specifically recognizing TrkA and uses thereof. The antibody includes a heavy chain variable region with an amino acid sequence shown in any one of SEQ ID NO: 2-8, and a light chain variable region with an amino acid sequence shown in any one of SEQ ID NO: 10-13. The above-mentioned antibody according to the embodiments of the present invention can specifically target and bind to the TrkA receptor and block the binding of NGF and TrkA.
    Type: Application
    Filed: November 18, 2021
    Publication date: November 9, 2023
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zhiheng REN, Junji DONG, Zhuandi HE, Kezhu WANG, Jielian LU, Shushan LIN, Liang LIU, Xiang LI, Kuo ZHANG, Yan JIANG, Xiaoping LI, Xiaofeng CHEN, Wenjia LI
  • Publication number: 20230257458
    Abstract: An antibody or an antigen-binding fragment can specifically recognize IL-11 thereof. The antibody contains CDR sequence(s) selected from at least one of the following or an amino acid sequence having at least 95% identity thereto: heavy chain variable region CDR sequences: SEQ ID NOs: 1-33 and light chain variable region CDR sequences: SEQ ID NOs: 34-66. The antibody can specifically target and bind to IL-11, so as to block binding of IL-11 and an IL-11 receptor.
    Type: Application
    Filed: August 12, 2021
    Publication date: August 17, 2023
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Jiatao ZHOU, Cangsha CHEN, Shujuan WANG, Jie YAO, Xiaofeng CHEN, Wenjia LI
  • Publication number: 20230235049
    Abstract: An invention provides a chimeric antigen receptor. The chimeric antigen receptor includes an extracellular domain including a heavy chain variable region, a light chain variable region of a single chain antibody fragment and CD8 hinge region; a transmembrane domain including an immune co-stimulator transmembrane domain; and an intracellular domain including an immune co-stimulator intracellular segment and CD3? chain. According to the embodiments of the invention, the chimeric antigen receptor can specifically recognize the tumor cells expressing the specific antigen and achieve the specific killing effect against the tumor cells expressing the high specific antigen.
    Type: Application
    Filed: August 11, 2020
    Publication date: July 27, 2023
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chao CHEN, Junji DONG, Tingting YU, Yi ZENG, Le XU, Xufang WANG, Zhiguang LI, Shaoyan LI, Qunrui YE, Xiaofeng CHEN, Wenjia LI
  • Patent number: 11679143
    Abstract: A fibroblast growth factor 21 (FGF21) variant, further to a FGF21 variant fusion protein, a protein multimer, and use thereof can significantly improve the binding ability with the target and can be used to treat metabolic diseases.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: June 20, 2023
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chao Chen, Shushan Lin, Yu Li, Xiaofeng Chen, Wenjia Li, Liang Liu, Zheng Fu
  • Publication number: 20220204630
    Abstract: An antibody or an antigen-binding fragment thereof is capable of specifically recognizing TrkA and uses thereof. The antibody contains a CDR sequence selected from at least one of the following or an amino acid sequence having at least 95% identity with it: heavy chain variable region CDR sequences: SEQ ID NO: 1˜27, light chain variable region CDR sequences: SEQ IN NO: 28˜54. The above antibody can specifically targeted-bind to the TrkA receptor and block the binding of NGF to TrkA.
    Type: Application
    Filed: May 28, 2020
    Publication date: June 30, 2022
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chao CHEN, Zhiheng REN, Zhuandi HE, Jielian LU, Shushan LIN, Tingting YU, Xiling WEI, Xufang WANG, Le XU, Junji DONG, Xiang LI, Kuo ZHANG, Xueyao YANG, Linfeng GUO, Xiaoping LI, Xiaofeng CHEN, Wenjia LI
  • Publication number: 20220064244
    Abstract: An FGF21 polypeptide has one or more of the following properties: stable structure, long half-life, low immunogenicity, high biological activity, and enhanced glucose-lowering and lipid-lowering activities. A fusion protein or immunoconjugate includes the FGF21 polypeptide.
    Type: Application
    Filed: March 4, 2020
    Publication date: March 3, 2022
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chao CHEN, Shushan LIN, Yu LI, Xiaoping LI, Xiaofeng CHEN, Wenjia LI, Liang LIU, Zheng FU
  • Publication number: 20220002938
    Abstract: The disclosure discloses a method for anti-felting finishing of wool fabric with protease K, and belongs to the technical field of dyeing and finishing of wool fabric in the wool spinning industry. The purpose is to solve the problems that common protease anti-felting treatment has greater damage to the strength of wool and has a weak degradation effect on keratin in a scale layer, thereby achieving the purpose of optimizing the anti-felting finishing of wool fabrics with protease. A preferred process is: pure wool fabric is first pretreated with urea peroxide, CMC is blocked with chitosan oligosaccharides, and then the wool fabric is treated with protease K. The wool fabric treated by the method has obviously improved anti-felting property, and the damage to the strength of the fabric is reduced. The disclosure introduces protease K into the anti-felting finishing of wool for the first time.
    Type: Application
    Filed: September 15, 2021
    Publication date: January 6, 2022
    Inventors: Qiang Wang, Wenjia Li, Yuanyuan Yu, Jiugang Yuan, Ping Wang, Xuerong Fan
  • Publication number: 20210341179
    Abstract: The present disclosure provides a photovoltaic-photothermal reaction complementary full-spectrum solar utilization system, comprising: a waveband thermal reactor having a reactant flow channel and a reaction chamber therein, a photovoltaic cell attached to a surface of the waveband thermal reactor, and a full spectrum concentrator configured to concentrate full spectrum sunlight onto a surface of the photovoltaic cell, wherein the full spectrum concentrating device concentrates the full spectrum sunlight onto a upper surface of the opaque or transmissive photovoltaic cell, wherein a portion of the sunlight is converted into electric energy and another portion of the sunlight is converted into thermal energy, and wherein the thermal energy is utilized by the waveband thermal reactor to preheat reactant(s) in the reaction chamber and to make a portion of the reactant(s) to undergo an endothermic chemical reaction such that the thermal energy is stored as chemical energy.
    Type: Application
    Filed: July 14, 2021
    Publication date: November 4, 2021
    Inventors: Hongguang JIN, Hui HONG, Yong HAO, Jie SUN, Yawen ZHAO, Wenjia LI, Qibin LIU
  • Patent number: 11092359
    Abstract: The present disclosure provides a photovoltaic-photothermal reaction complementary full-spectrum solar utilization system, comprising: a waveband thermal reactor having a reactant flow channel and a reaction chamber therein, a photovoltaic cell attached to a surface of the waveband thermal reactor, and a full spectrum concentrator configured to concentrate full spectrum sunlight onto a surface of the photovoltaic cell, wherein the full spectrum concentrating device concentrates the full spectrum sunlight onto a upper surface of the opaque or transmissive photovoltaic cell, wherein a portion of the sunlight is converted into electric energy and another portion of the sunlight is converted into thermal energy, and wherein the thermal energy is utilized by the waveband thermal reactor to preheat reactant(s) in the reaction chamber and to make a portion of the reactant(s) to undergo an endothermic chemical reaction such that the thermal energy is stored as chemical energy.
    Type: Grant
    Filed: February 6, 2016
    Date of Patent: August 17, 2021
    Assignee: Institute of Engineering Thermophysics, Chinese Academy of Sciences
    Inventors: Hongguang Jin, Hui Hong, Yong Hao, Jie Sun, Yawen Zhao, Wenjia Li, Qibin Liu